Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TCF4 | P15884 | 1/20 | 0.67 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | GPR27 | Q9NS67 | 2/20 | 0.60 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532190 | 0.91 | MEN1 (0.71) | TCF4CTNNB1MEN1KMT2AALDH1A1 | |
| SCHEMBL30600087 | 0.90 | MEN1 (0.70) | MEN1KMT2AALDH1A1EGFRFGFR1 | |
| SCHEMBL2824634 | 0.90 | MEN1 (0.70) | MEN1KMT2AALDH1A1EGFRFGFR1 | |
| SCHEMBL16430148 | 0.90 | TCF4 (0.66) | TCF4CTNNB1MEN1KMT2AALDH1A1 | |
| SCHEMBL13532193 | 0.90 | MEN1 (0.74) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3720429 | 0.88 | TCF4 (0.81) | TCF4CTNNB1MEN1KMT2AALDH1A1 | |
| SCHEMBL2825370 | 0.87 | KMT2A (0.79) | MEN1KMT2AEGFRFGFR1KDR | |
| SCHEMBL2826756 | 0.86 | SMN1; SMN2 (0.69) | TCF4CTNNB1MEN1KMT2AALDH1A1 | |
| SCHEMBL27179735 | 0.86 | MEN1 (0.71) | MEN1KMT2AALDH1A1EGFRFGFR1 | |
| SCHEMBL30926669 | 0.85 | SMN1; SMN2 (0.68) | TCF4CTNNB1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2012-09-13 | — | — | US | claimed |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2011-12-29 | — | — | US | claimed |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD | 2010-06-10 | — | — | US | claimed |
| US-7723538-B2 | enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid | HOFFMANN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | claimed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1891001-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-02-27 | — | — | EP | claimed |
| WO-2006131452-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-14 | — | — | WO | claimed |
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | claimed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022212568-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | BLEICHER KONRAD | 2010-06-10 | — | — | US | disclosed |
| US-7723538-B2 | enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid | HOFFMANN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1891001-B1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-1891001-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006131452-A1 | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-14 | — | — | WO | disclosed |
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276494-A1 | Novel sulfonamides as L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | TCF4 2219/4885CTNNB1 3692/4885MEN1 4442/4885 |
| US-20120232104-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | TCF4 2219/4885CTNNB1 3692/4885MEN1 4442/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | TCF4 3553/4885CTNNB1 4204/4885MEN1 4713/4885 |
| US-20100144762-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | TCF4 2219/4885CTNNB1 3692/4885MEN1 4442/4885 |
| US-20110319438-A1 | NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | TCF4 2219/4885CTNNB1 3692/4885MEN1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.